Get the Stockscreener App
0.90
3.24%
-0.0301
After Hours:
.90
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Forecast
The Barinthus Biotherapeutics Plc Adr (BRNS) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $0.9412, representing a +4.58% increase from the current price of $0.90. The highest analyst price target is $1.4381, and the lowest is $0.4443.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month BRNS Price Target
Average 1.1169
(+24.10% Upside)
Is Barinthus Biotherapeutics Plc Adr (BRNS) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 44.59 | Neutral |
| STOCH(9,6) | 3.9995 | Buy |
| STOCHRSI(14) | 4.0972 | Buy |
| MACD(12,26) | -0.000382 | Sell |
| ADX(14) | 12.19 | Neutral |
| William %R | -92.95 | Buy |
| CCI(14) | -69.58 | Neutral |
Buy: 3
Sell: 1
Neutral: 3
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
0.9417
Sell
|
0.9253
Sell
|
| MA20 |
0.937
Sell
|
0.9326
Sell
|
| MA50 |
0.8845
Sell
|
0.9241
Sell
|
| MA100 |
0.9355
Sell
|
0.96
Sell
|
| MA200 |
1.0504
Sell
|
1.1611
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, BRNS could be considered a Strong Sell, with 17 technical analysis indicators signaling 3 Buy signals, 11 signaling Sell signals and 3 Neutral signals. This might not be a good time to consider opening new positions on BRNS, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 44.59 indicates that BRNS is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 3.9995 indicates that BRNS is oversold. This indicates that BRNS price is at or near the lowest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 4.0972 indicates that BRNS is oversold. This suggests that BRNS price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 12.19 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -69.58 indicates that BRNS is still oversold but not to an extreme extent.
Long-term BRNS price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Barinthus Biotherapeutics Plc Adr financial reports and earnings history, Barinthus Biotherapeutics Plc Adr (BRNS) stock could reach $3.7977 by 2030, $17.82 by 2040 and $27.50 by 2050. See the projected annual prices until 2050 of the Barinthus Biotherapeutics Plc Adr stock below:
- Barinthus Biotherapeutics Plc Adr (BRNS) is expected to reach an average price of $10.16 in 2035, with a high prediction of $10.58 and a low estimate of $10.04. This indicates an $1,029% rise from the last recorded price of $0.90.
- Barinthus Biotherapeutics Plc Adr (BRNS) stock is projected to chart a bullish course in 2040, with an average price target of $17.52, representing an $1,847% surge from its current level. The forecast ranges from a conservative $17.57 to a sky-high $17.82.
- Our analysts predict Barinthus Biotherapeutics Plc Adr (BRNS) to jump 2,935% by 2045, soaring from $19.74 to an average price of $27.32, potentially reaching $26.82. While $19.74 is the low estimate, the potential upside is significant.
- Barinthus Biotherapeutics Plc Adr (BRNS) stock is expected to climb by 2050, reaching an average of $26.97, a $2,897% jump from its current level. However, a wide range of estimates exists, with high and low targets of $27.50 and $27.38, respectively, highlighting the market's uncertainty.
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Year by Year Forecast
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Price Forecast for 2025
Barinthus Biotherapeutics Plc Adr Stock (BRNS) is expected to reach an average price of $1.4438 in 2025, with a high prediction of $2.8753 and a low estimate of $0.0123. This indicates an +60.42% rise from the last recorded price of $0.90.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| August, 2025 | $1.4081 | $0.4443 | $1.4381 | +56.46% |
| September, 2025 | $0.7071 | $0.4072 | $1.5304 | -21.44% |
| October, 2025 | $0.6085 | $0.3262 | $0.7974 | -32.39% |
| November, 2025 | $0.4822 | $0.4376 | $1.1844 | -46.43% |
| December, 2025 | $0.6289 | $0.1998 | $2.2335 | -30.12% |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Price Forecast for 2026
The predicted value for Barinthus Biotherapeutics Plc Adr (BRNS) in 2026 is set at an average of $0.796. Estimates vary from a peak of $1.5916 to a trough of $0.000394, indicating an -11.56% surge from the present price of $0.90.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $0.26 | $0.0166 | $1.1098 | -71.11% |
| February, 2026 | $0.0113 | $0.1413 | $0.0706 | -98.75% |
| March, 2026 | $0.6475 | $0.000394 | $0.6775 | -28.06% |
| April, 2026 | $0.1441 | $0.0534 | $0.7772 | -83.99% |
| May, 2026 | $0.0853 | $0.2044 | $0.1047 | -90.52% |
| June, 2026 | $0.182 | $0.0556 | $0.5128 | -79.78% |
| July, 2026 | $0.00185 | $0.00185 | $1.5916 | -99.79% |
| August, 2026 | $1.08 | $0.0785 | $0.2898 | +20.00% |
| September, 2026 | $0.8765 | $0.9316 | $0.8758 | -2.62% |
| October, 2026 | $0.246 | $0.246 | $0.3774 | -72.66% |
| November, 2026 | $0.8676 | $0.5689 | $0.6496 | -3.60% |
| December, 2026 | $0.6021 | $0.7421 | $0.8134 | -33.11% |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Barinthus Biotherapeutics Plc Adr (BRNS) is $1.3517, with a high forecast of $2.4861 and a low forecast of $0.2173. This indicates an +50.19% increase from the last price of $0.90.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $0.7037 | $0.5349 | $0.6837 | -21.81% |
| February, 2027 | $0.6252 | $0.2173 | $0.9497 | -30.53% |
| March, 2027 | $2.1255 | $0.6981 | $1.6255 | +136.16% |
| April, 2027 | $1.6594 | $1.7219 | $1.6809 | +84.37% |
| May, 2027 | $0.9992 | $0.9992 | $1.1528 | +11.03% |
| June, 2027 | $1.6166 | $1.3147 | $1.4236 | +79.62% |
| July, 2027 | $1.2885 | $1.4285 | $1.5221 | +43.16% |
| August, 2027 | $1.3604 | $1.2139 | $1.3404 | +51.16% |
| September, 2027 | $1.2177 | $0.8518 | $1.4258 | +35.30% |
| October, 2027 | $2.938 | $1.5986 | $2.438 | +226.45% |
| November, 2027 | $2.4422 | $2.5122 | $2.4861 | +171.36% |
| December, 2027 | $1.8605 | $1.7524 | $1.9283 | +106.72% |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Price Forecast for 2028
In 2028, Barinthus Biotherapeutics Plc Adr (BRNS) is projected to reach an average price of $2.7913, with a high projection of $4.0964 and a low estimate of $1.4862. This indicates an +210.15% rise from the last price of $0.90.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $2.3327 | $2.2685 | $2.1397 | +159.19% |
| February, 2028 | $1.9749 | $2.1149 | $2.2307 | +119.43% |
| March, 2028 | $2.1651 | $1.8929 | $2.0751 | +140.57% |
| April, 2028 | $1.8373 | $1.4862 | $1.6773 | +104.15% |
| May, 2028 | $3.4913 | $2.2034 | $3.2913 | +287.92% |
| June, 2028 | $2.9438 | $3.3025 | $3.2119 | +227.08% |
| July, 2028 | $2.6063 | $2.5056 | $2.4544 | +189.59% |
| August, 2028 | $3.1094 | $3.0069 | $2.9394 | +245.49% |
| September, 2028 | $2.4819 | $2.5719 | $2.87 | +175.77% |
| October, 2028 | $2.8144 | $2.8726 | $2.7244 | +212.71% |
| November, 2028 | $2.8476 | $2.1207 | $2.3076 | +216.39% |
| December, 2028 | $4.2964 | $2.8082 | $4.0964 | +377.38% |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Price Forecast for 2029
The 2029 price forecast for Barinthus Biotherapeutics Plc Adr Stock (BRNS) is $3.8283 on average, with a high prediction of $4.9016 and a low estimate of $2.7551. This represents an +325.37% increase from the previous price of $0.90.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $3.6024 | $3.8406 | $4.0096 | +300.27% |
| February, 2029 | $3.4453 | $3.2588 | $3.2753 | +282.81% |
| March, 2029 | $3.8181 | $3.7849 | $3.6481 | +324.23% |
| April, 2029 | $3.1609 | $3.2509 | $3.5713 | +251.21% |
| May, 2029 | $2.4769 | $3.4069 | $3.3737 | +175.21% |
| June, 2029 | $3.4597 | $2.7551 | $2.9197 | +284.42% |
| July, 2029 | $5.1016 | $3.413 | $4.9016 | +466.84% |
| August, 2029 | $4.3705 | $4.6087 | $4.8074 | +385.61% |
| September, 2029 | $4.1836 | $4.0121 | $4.0136 | +364.85% |
| October, 2029 | $4.5025 | $4.501 | $4.3568 | +400.28% |
| November, 2029 | $4.1157 | $3.9299 | $4.1183 | +357.30% |
| December, 2029 | $3.1188 | $4.0488 | $4.023 | +246.53% |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Price Forecast for 2030
Barinthus Biotherapeutics Plc Adr Stock (BRNS) is expected to reach an average price of $4.9507 in 2030, with a high forecast of $6.5119 and a low forecast of $3.3896. This signifies an +450.08% surge from the last price of $0.90.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $3.5937 | $3.3896 | $3.7977 | +299.30% |
| February, 2030 | $5.9202 | $6.0251 | $5.7067 | +557.80% |
| March, 2030 | $5.1385 | $5.3767 | $5.506 | +470.95% |
| April, 2030 | $4.922 | $4.7653 | $4.752 | +446.89% |
| May, 2030 | $5.2038 | $5.2171 | $5.0654 | +478.20% |
| June, 2030 | $4.7872 | $4.6089 | $4.8122 | +431.92% |
| July, 2030 | $3.8391 | $4.0241 | $4.6723 | +326.56% |
| August, 2030 | $4.395 | $4.3874 | $4.4025 | +388.33% |
| September, 2030 | $6.7179 | $6.8228 | $6.5119 | +646.44% |
| October, 2030 | $5.4375 | $5.9055 | $6.2964 | +504.17% |
| November, 2030 | $5.8714 | $5.5185 | $5.6413 | +552.38% |
| December, 2030 | $5.905 | $5.9332 | $5.7741 | +556.12% |
0.39%
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):